Cargando…

Correction: On the mechanism of anti-CD39 immune checkpoint therapy

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402001/ https://www.ncbi.nlm.nih.gov/pubmed/32747468 http://dx.doi.org/10.1136/jitc-2019-000186corr1

Ejemplares similares

On the mechanism of anti-CD39 immune checkpoint therapy
por: Allard, David, et al.
Publicado: (2020)

Correction: Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
por: Kiaie, Seyed Hossein, et al.
Publicado: (2023)

Correction: Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Publicado: (2022)

Correction: Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
Publicado: (2020)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020)

Correction: Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
Publicado: (2023)

Author Correction: CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas
por: Niborski, Leticia Laura, et al.
Publicado: (2023)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Correction: Immune checkpoint inhibitor-associated celiac disease
Publicado: (2020)

Correction: T lymphocyte-targeted immune checkpoint modulation in glioma
Publicado: (2020)

Correction: Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

Correction to: Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade
por: Natoli, Marina, et al.
Publicado: (2020)

Correction to: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Correction to Lancet Infect Dis 2019; 19: 728–39
Publicado: (2020)

Correction to Lancet Haematol 2021; 8: e828–39
Publicado: (2021)

Correction: Acute kidney injury in patients treated with immune checkpoint inhibitors
Publicado: (2023)

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2023)

Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
por: Tallantyre, E. C., et al.
Publicado: (2018)

Correction: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Publicado: (2021)

Correction to Lancet Child Adolesc Health 2022; 6: 230–39
Publicado: (2022)

Correction: Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity
Publicado: (2017)

Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
por: Gao, Mei, et al.
Publicado: (2020)

Correction: MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
Publicado: (2020)

Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2023)

Author Correction: NADH oxidase-dependent CD39 expression by CD8(+) T cells modulates interferon gamma responses via generation of adenosine
por: Bai, Aiping, et al.
Publicado: (2020)

Publisher Correction: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
por: Beug, Shawn T., et al.
Publicado: (2018)

Correction: Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
Publicado: (2021)

Correction to: Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma
por: Wu, Xiaobin, et al.
Publicado: (2021)

Authors’ correction for Euro Surveill. 2020;25(39)
Publicado: (2020)

Authors’ correction for Euro Surveill. 2018;23(39)
Publicado: (2018)

Author's correction for Euro Surveill. 2022;27(39)
Publicado: (2022)

Correction: Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML
Publicado: (2021)

Correction: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
Publicado: (2020)

Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Publicado: (2021)

Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Publicado: (2022)

Correction: On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
Publicado: (2021)

Correction: Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
por: Kim, Min Hwan, et al.
Publicado: (2020)

Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses
por: Shevchenko, Ivan, et al.
Publicado: (2020)

Correction: Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy
Publicado: (2021)

Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
por: Kashyap, Abhishek S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kal305vs5t1askeb0piueinc7c